Investment area



Date of investment

March 2022

Qure.ai has created a niche for itself with advanced technology that reads and interprets medical images such as X-rays, CTs and ultrasounds in less than a minute, making equitable and high-quality healthcare a reality across the globe. Qure’s AI solutions are FDA-approved, CE-certified and evaluated by the World Health Organization.

Qure.ai’s automated medical imaging tools can shorten the time to diagnosis while enabling physicians to triage medical cases more effectively, especially in time-sensitive situations. This helps healthcare providers to identify critical scenarios within minutes – versus hours – to avert fatalities and improve the quality of patient care. In other settings, where adequate, skilled specialists may not be available, Qure’s technology is used as the first level of screening for many infections and noncommunicable conditions.

Visit site


Amit Kakar

Managing Partner

Department: Novo Holdings Asia

Amit joined Novo Holdings Asia in August 2020 as Head of Asia to lead investments and partnerships across the region, focusing primarily on the markets in China, Japan, Singapore and Southeast Asia.

Amit has more than 25 years of healthcare experience with several senior management roles across the globe and having worked in India, China, Singapore and the USA. Previously, he has been with Everlife Asia based in Singapore as Head of M&A and Business Development, with the Avenue Capital Group as Head of healthcare investments for Asia and with GE Healthcare in several senior leadership positions.

Amit is a Medical Doctor with a postgraduate degree in Radiation and Nuclear Medicine from Tata Memorial Hospital and Cancer Centre in Mumbai, India.